Comparative effectiveness and safety of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in type 2 diabetes mellitus: rapid review of systematic reviews and meta-analyzes
PDF (Español (España))
HTML (Español (España))

Keywords

Sodium-Glucose Transporter 2 Inhibitors
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Kidney Diseases
Hypoglycemia

How to Cite

Chacón, K., Mendivelso, F., Gómez, O., González , C., Pinto, D., Yama, E., Moscoso, E., Acevedo, J., Bohórquez, L., Rincón, O., Ruiz, P., Espitia Malagón , R., Isaza, M., Aroca, G., Tovar, H., Luján, D., Rodríguez, M., Hamann, O., & Yomayusa, N. (2021). Comparative effectiveness and safety of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in type 2 diabetes mellitus: rapid review of systematic reviews and meta-analyzes. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(4), 222–234. https://doi.org/10.53853/encr.7.4.648

Abstract

Aim: To evaluate the evidence of effectiveness and safety of sodium glucose co-transporter inhibitors type 2 (iSGLT2) in patients with type 2 diabetes mellitus.

Methodology: A rapid systematic review of systematic reviews of iSGLT2 was performed in the Medline and Embase databases until September 2019. Cardiovascular outcome was major cardiovascular adverse events (MACE): death due to cardiovascular causes, non-fatal stroke and acute non-fatal myocardial infarction, in addition to hospitalization for heart failure; renal outcome was progression of renal disease, decrease in glomerular filtration rate and albumin-creatinine ratio. The safety outcome comprehended hypoglycemia, fractures, and urinary infections. The methodological quality was evaluated with the modified A measurement Tool to Assess Systematic Review (AMSTAR-2) tool.

Results: Five systematic reviews of the literature of medium and high-quality AMSTAR-2 were included. The iSGLT2 reduces the risk of cardiovascular mortality by 23%, from all-cause mortality by 20% and in hospital admission for heart failure in 33% versus standard care. In addition, the iSGLT2 slows the deterioration of renal disease and reduces the progression to albumin in patients with documented proteinuria. In the safety outcome, there is a greater possibility of developing genitourinary tract infections with respect to oral antidiabetics.

Conclusions: The evidence suggests that iSGLT2 are effective in reducing the risk of cardiovascular mortality, all-cause mortality, hospital admission for heart failure, progression of nephropathy and the development of end-stage renal disease. In safety outcomes, the evidence suggests that iSGLT2 have a lower risk of hypoglycemic events.

https://doi.org/10.53853/encr.7.4.648
PDF (Español (España))
HTML (Español (España))

References

Informe mundial sobre la diabetes. Resumen de orientación [internet]. Organización Mundial de la Salud; 2016 [citado 08 de noviembre de 2019] Disponible en: https://apps.who.int/iris/bitstream/handle/10665/204877/WHO_NMH_,NVI_16.3_spa.pdf;jsessionid=AF6B34075D78F05440BCD7468DEA6FE2?sequence=1

Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME; 2018.

Herrera AB. Análisis de Situación de Salud (ASIS) Colombia, 2018. Ministerio de salud y Protección Social; 2019.

Boletín de información técnica especializada de la cuenta de alto costo. CAC. 2018;4(17):1-6.

Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Bogotá: Ministerio de Salud y Protección Social de Colombia; 2016.

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854.

Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sci Rep. 2019;9(1):13009.

Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J Diabetes Complications. 2015;29(8):1295-303.

Xu L, Li Y, Lang J, Xia P, Zhao X, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ. 2017;5:e3405.

Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabet Med. 2019;36(4):444-452.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.